Phibro Animal Health (PAHC) 10-Q 2018 Q1 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-36410

Phibro Animal Health Corporation

(Exact name of registrant as specified in its charter)

Delaware	13-1840497
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, New Jersey (Address of Principal Executive Offices) 07666-6712 (Zip Code)

(201) 329-7300

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.)  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of  “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	​	Accelerated filer	☒
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐
Emerging growth company	☒	​	​	​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2017, there were 19,581,889 shares of the registrant’s Class A common stock, par value $0.0001 per share, and 20,602,836 shares of the registrant’s Class B common stock, par value $0.0001 per share, outstanding.

PHIBRO ANIMAL HEALTH CORPORATION

TABLE OF CONTENTS

​	Page
PART I—FINANCIAL INFORMATION	​
Item 1. Financial Statements (unaudited)	​	3
Consolidated Statements of Operations	​	3
Consolidated Statements of Comprehensive Income	​	4
Consolidated Balance Sheets	​	5
Consolidated Statements of Cash Flows	​	6
Notes to Consolidated Financial Statements	​	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of    Operations	​	17
Item 3. Quantitative and Qualitative Disclosures About Market Risk	​	26
Item 4. Controls and Procedures	​	27
PART II—OTHER INFORMATION	​
Item 1. Legal Proceedings	​	28
Item 1A. Risk Factors	​	28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	​	28
Item 3. Defaults Upon Senior Securities	​	28
Item 4. Mine Safety Disclosures	​	28
Item 5. Other Information	​	28
Item 6. Exhibits	​	28
SIGNATURES	​	29

2

PART I—FINANCIAL INFORMATION

Item 1.   Financial Statements

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

​	Three Months
For the Periods Ended September 30	2017			2016
​	(unaudited) (in thousands, except per share amounts)
Net sales	​	$	193,412	​	$	187,987
Cost of goods sold	​	​	130,030	​	​	126,988
Gross profit	​	​	63,382	​	​	60,999
Selling, general and administrative expenses	​	​	40,995	​	​	39,186
Operating income	​	​	22,387	​	​	21,813
Interest expense, net	​	​	3,118	​	​	3,907
Foreign currency (gains) losses, net	​	​	325	​	​	334
Income before income taxes	​	​	18,944	​	​	17,572
Provision (benefit) for income taxes	​	​	3,052	​	​	5,395
Net income	​	$	15,892	​	$	12,177
Net income per share	​			​
basic	​	$	0.40	​	$	0.31
diluted	​	$	0.39	​	$	0.31
Weighted average common shares outstanding	​			​
basic	​	​	39,944	​	​	39,408
diluted	​	​	40,293	​	​	39,906
Dividends per share	​	$	0.10	​	$	0.10

The accompanying notes are an integral part of these consolidated financial statements

3

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

​	Three Months
For the Periods Ended September 30	2017			2016
​	(unaudited) (in thousands)
Net income	​	$	15,892	​	$	12,177
Change in fair value of derivative instruments	​	​	(622)	​	​	34
Foreign currency translation adjustment	​	​	3,233	​	​	(893)
Unrecognized net pension gains (losses)	​	​	131	​	​	7,169
(Provision) benefit for income taxes	​	​	187	​	​	(2,750)
Other comprehensive income (loss)	​	​	2,929	​	​	3,560
Comprehensive income	​	$	18,821	​	$	15,737

The accompanying notes are an integral part of these consolidated financial statements

4

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

As of	September 30, 2017			June 30, 2017
​	(unaudited) (in thousands, except share and per share amounts)
ASSETS	​			​
Cash and cash equivalents	​	$	62,097	​	$	56,083
Accounts receivable, net	​	​	136,337	​	​	125,847
Inventories, net	​	​	170,928	​	​	161,233
Other current assets	​	​	25,193	​	​	20,502
Total current assets	​	​	394,555	​	​	363,665
Property, plant and equipment, net	​	​	131,242	​	​	127,351
Intangibles, net	​	​	64,457	​	​	54,602
Goodwill	​	​	23,982	​	​	23,982
Other assets	​	​	56,875	​	​	53,797
Total assets	​	$	671,111	​	$	623,397
LIABILITIES AND STOCKHOLDERS’ EQUITY	​			​
Current portion of long-term debt	​	$	7,895	​	$	6,250
Accounts payable	​	​	61,732	​	​	56,894
Accrued expenses and other current liabilities	​	​	51,480	​	​	52,652
Total current liabilities	​	​	121,107	​	​	115,796
Revolving credit facility	​	​	85,000	​	​	65,000
Long-term debt	​	​	238,959	​	​	241,891
Other liabilities	​	​	56,570	​	​	49,553
Total liabilities	​	​	501,636	​	​	472,240
Commitments and contingencies (Note 8)	​			​
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 19,555,839 and 19,249,132 shares issued and outstanding at September 30, 2017, and June 30, 2017, respectively; 30,000,000 Class B shares authorized, 20,614,836 and 20,626,836 shares issued and outstanding at September 30, 2017, and June 30, 2017, respectively	​	​	4	​	​	4
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding	​	​	—	​	​	—
Paid-in capital	​	​	127,326	​	​	123,840
Retained earnings	​	​	94,653	​	​	82,750
Accumulated other comprehensive income (loss)	​	​	(52,508)	​	​	(55,437)
Total stockholders’ equity	​	​	169,475	​	​	151,157
Total liabilities and stockholders’ equity	​	$	671,111	​	$	623,397

The accompanying notes are an integral part of these consolidated financial statements

5

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

​	Three Months
For the Periods Ended September 30	2017			2016
​	(unaudited) (in thousands)
OPERATING ACTIVITIES	​			​
Net income	​	$	15,892	​	$	12,177
Adjustments to reconcile net income to net cash provided (used) by operating activities:	​			​
Depreciation and amortization	​	​	6,644	​	​	6,318
Amortization of debt issuance costs and debt discount	​	​	221	​	​	253
Acquisition-related cost of goods sold	​	​	249	​	​	—
Acquisition-related accrued compensation	​	​	437	​	​	420
Acquisition-related accrued interest	​	​	253	​	​	393
Deferred income taxes	​	​	770	​	​	1,706
Foreign currency (gains) losses, net	​	​	345	​	​	97
Other	​	​	213	​	​	87
Changes in operating assets and liabilities, net of business acquisition:	​			​
Accounts receivable, net	​	​	(8,386)	​	​	3,906
Inventories, net	​	​	(5,196)	​	​	4,544
Other current assets	​	​	(4,458)	​	​	(2,430)
Other assets	​	​	332	​	​	346
Accounts payable	​	​	3,652	​	​	(5,004)
Accrued expenses and other liabilities	​	​	(6,165)	​	​	(1,357)
Net cash provided (used) by operating activities	​	​	4,803	​	​	21,456
INVESTING ACTIVITIES	​			​
Capital expenditures	​	​	(4,998)	​	​	(5,911)
Business acquisition	​	​	(11,562)	​	​	—
Other, net	​	​	(272)	​	​	25
Net cash provided (used) by investing activities	​	​	(16,832)	​	​	(5,886)
FINANCING ACTIVITIES	​			​
Revolving credit facility borrowings	​	​	61,870	​	​	34,000
Revolving credit facility repayments	​	​	(41,870)	​	​	(41,000)
Payments of long-term debt, capital leases and other	​	​	(1,652)	​	​	(729)
Proceeds from common shares issued	​	​	3,486	​	​	—
Dividends paid	​	​	(3,989)	​	​	(3,941)
Net cash provided (used) by financing activities	​	​	17,845	​	​	(11,670)
Effect of exchange rate changes on cash	​	​	198	​	​	(90)
Net increase (decrease) in cash and cash equivalents	​	​	6,014	​	​	3,810
Cash and cash equivalents at beginning of period	​	​	56,083	​	​	33,605
Cash and cash equivalents at end of period	​	$	62,097	​	$	37,415

The accompanying notes are an integral part of these consolidated financial statements

6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share amounts)
(unaudited)

1.

Description of Business

Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, cattle, dairy and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries.

The unaudited consolidated financial information for the three months ended September 30, 2017 and 2016, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 (the “Annual Report”), filed with the Securities and Exchange Commission on August 30, 2017 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2017, was derived from the audited consolidated financial statements, which include the accounts of Phibro and its consolidated subsidiaries, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.

The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated in the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

2.

Summary of Significant Accounting Policies and New Accounting Standards

Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of September 30, 2017, there have been no material changes to any of the significant accounting policies contained therein.

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the assumed exercise of stock options. For the three months ended September 30, 2017 and 2016, all common share equivalents were included in the calculation of diluted net income per share.

7

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

​	Three Months
For the Periods Ended September 30	2017			2016
Net income	​	$	15,892	​	$	12,177
Weighted average number of shares – basic	​	​	39,944	​	​	39,408
Dilutive effect of stock options	​	​	349	​	​	498
Weighted average number of shares – diluted	​	​	40,293	​	​	39,906
Net income per share	​			​
basic	​	$	0.40	​	$	0.31
diluted	​	$	0.39	​	$	0.31

Dividends

We declared and paid quarterly cash dividends of $0.10 per share, totaling $3,989 during the three months ended September 30, 2017, to holders of our Class A common stock and Class B common stock.

New Accounting Standards

Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities simplifies the application of hedge accounting guidance and improves the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. During the three months ended September 30, 2017, we elected early adoption of this guidance and applied the qualitative method, and it did not have a material effect on our consolidated financial statements. For additional details, see “—Derivatives.”

ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, provides specific guidance for the classification of certain transactions within the statement of cash flows. The issues addressed by this guidance include, but are not limited to, debt prepayments or debt extinguishment costs, contingent consideration payments made after a business combination and proceeds from the settlement of insurance claims. This ASU is effective for annual reporting periods beginning after December 15, 2017. Early application is permitted, as long as all provisions under the guidance are applied simultaneously. The provisions of this guidance are to be applied using a retrospective transition approach. We do not expect adoption of this guidance to have a material effect on our consolidated financial statements.

ASU 2016-02, Leases (Topic 842), supersedes the current lease accounting guidance, requires an entity to recognize assets and liabilities for both financing and operating leases on the balance sheet and requires additional qualitative and quantitative disclosures regarding leasing arrangements. This ASU is effective for annual reporting periods beginning after December 15, 2018. We are evaluating the effect of adoption of this guidance on our consolidated financial statements.

ASU 2015-11, Inventory (Topic 330), requires entities to measure inventory at the lower of cost and net realizable value (“NRV”). NRV is defined as “the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” We applied this guidance during the three months ended September 30, 2017, and it did not have a material effect on our consolidated financial statements.

ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. ASU 2014-09 and its amendments are effective for our consolidated financial statements beginning July 1, 2018. We expect to apply the new standard using the modified retrospective method. We continue to evaluate the effect that the adoption of this guidance may have on our consolidated financial statements.

8

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

3.

Statements of Operations—Additional Information

​	Three Months
For the Periods Ended September 30	2017			2016
Interest expense, net	​			​
Term loan	​	$	2,033	​	$	2,905
Revolving credit facility	​	​	681	​	​	955
Amortization of debt issuance costs and debt discount	​	​	221	​	​	253
Acquisition-related accrued interest	​	​	253	​	​	393
Other	​	​	239	​	​	81
Interest expense	​	​	3,427	​	​	4,587
Interest (income)	​	​	(309)	​	​	(680)
​	​	$	3,118	​	$	3,907
Depreciation and amortization	​			​
Depreciation of property, plant and equipment	​	$	5,183	​	$	4,731
Amortization of intangible assets	​	​	1,449	​	​	1,528
Amortization of other assets	​	​	12	​	​	59
​	​	$	6,644	​	$	6,318

4.

Balance Sheets—Additional Information

As of	September 30, 2017			June 30, 2017
Inventories	​			​
Raw materials	​	$	57,719	​	$	54,861
Work-in-process	​	​	12,014	​	​	12,402
Finished goods	​	​	101,195	​	​	93,970
​	​	$	170,928	​	$	161,233

In September 2017, we acquired a business for approximately $15,000, including approximately $3,500 paid subsequent to September 30, 2017. The business develops, manufactures and markets animal health products. We accounted for the acquisition as a business combination in accordance with ASC 805, Business Combinations. Pro forma information giving effect to the acquisition has not been provided because the results are not material to the consolidated financial statements. Net assets acquired included accounts receivable, inventories, property, plant and equipment, intangible assets, accounts payable and accrued expenses. We expect to refine the valuation of certain assets and liabilities during the measurement period. The business is included in the Animal Health segment.

Goodwill balances did not change during the three months ended September 30, 2017.

We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $3,802 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.

9

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

As of	September 30, 2017			June 30, 2017
Accrued expenses and other current liabilities	​			​
Employee related	​	$	21,030	​	$	26,553
Commissions and rebates	​	​	4,964	​	​	6,443
Insurance related	​	​	1,522	​	​	1,515
Professional fees	​	​	3,513	​	​	3,823
Income and other taxes	​	​	3,631	​	​	3,035
Other	​	​	16,820	​	​	11,283
​	​	$	51,480	​	$	52,652

As of	September 30, 2017			June 30, 2017
Accumulated other comprehensive income (loss)	​	​	​	​	​	​
Derivative instruments	​	$	2,064	​	$	2,686
Foreign currency translation adjustment	​	​	(40,323)	​	​	(43,556)
Unrecognized net pension gains (losses)	​	​	(17,928)	​	​	(18,059)
(Provision) benefit for income taxes on derivative instruments	​	​	(1,316)	​	​	(1,553)
(Provision) benefit for incomes taxes on long-term intercompany investments	​	​	8,166	​	​	8,166
(Provision) benefit for income taxes on pension gains (losses)	​	​	(3,171)	​	​	(3,121)
​	​	$	(52,508)	​	$	(55,437)

5.

Debt

Term Loans and Revolving Credit Facilities

Pursuant to a credit agreement (the “Credit Agreement”), we have a revolving credit facility (the “Revolver”), where we can borrow up to $250,000, subject to the terms of the agreement, and a term A loan with an aggregate initial principal amount of  $250,000 (the “Term A Loan,” and together with the Revolver, the “Credit Facilities”). The Credit Facilities have applicable margins equal to 2.00%, 1.75% or 1.50%, in the case of LIBOR and Eurodollar rate loans and 1.00%, 0.75% or 0.50%, in the case of base rate loans; the applicable margins are based on the First Lien Net Leverage Ratio. The libor rate is subject to a floor of 0.00%.

The Credit Facilities require, among other things, the maintenance of  (i) a maximum consolidated first lien net debt to consolidated EBITDA leverage ratio and (ii) a minimum consolidated interest coverage ratio, each calculated on a trailing four quarter basis, and contain an acceleration clause should an event of default (as defined in the agreement governing the Credit Facilities) occur. As of September 30, 2017, we were in compliance with the covenants of the Credit Facilities. The Credit Facilities mature on June 29, 2022.

As of September 30, 2017, we had $85,000 in borrowings under the Revolver and had outstanding letters of credit of  $4,651, leaving $160,349 available for borrowings and letters of credit under the Revolver. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are one year or less.

The weighted-average interest rates for the Revolver and Term A Loan were 2.98% and 3.22%, respectively, for the three months ended September 30, 2017.

In July 2017, we entered into an interest rate swap agreement on $150 million of notional principal that effectively converts the floating LIBOR or base rate portion of our interest obligation on that amount

10

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. The interest rate swap has been designated as a highly effective cash flow hedge. For additional details, see “—Derivatives.”

Long-Term Debt

As of	September 30, 2017			June 30, 2017
Term A Loan due June 2022	​	$	248,438	​	$	250,000
Capitalized lease obligations	​	​	182	​	​	—
​	​	​	248,620	​	​	250,000
Unamortized debt issuance costs and debt discount	​	​	(1,766)	​	​	(1,859)
​	​	​	246,854	​	​	248,141
Less: current maturities	​	​	(7,895)	​	​	(6,250)
​	​	$	238,959	​	$	241,891

6.

Related Party Transactions

Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to us as employees or consultants and received aggregate compensation and benefits of approximately $720 and $603 during the three months ended September 30, 2017 and 2016. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

7.

Employee Benefit Plans

The Company maintains a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. Plan benefits are based upon years of service and average compensation, as defined.

In July 2016, we amended the domestic noncontributory defined benefit pension plan to eliminate credit for future service and compensation increases, effective as of September 30, 2016. The amendment resulted in a curtailment of the pension plan. During the three months ended September 30, 2016, we recorded a pension curtailment gain of $6,822 in other comprehensive income and an offsetting reduction in the liability for pension benefits included in other liabilities.

8.

Commitments and Contingencies

Environmental

Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.

11

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.

The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of a facility in Santa Fe Springs, California, operated by our subsidiary Phibro-Tech, Inc. (“Phibro-Tech”). The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that groundwater contamination at its site is due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a nearby property owner has filed a complaint in the Superior Court of the State of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for alleged contamination of groundwater underneath its property, and a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA, RCRA and the common law public nuisance doctrine in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA’s investigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.

Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be approximately $6,898 and $7,211 at September 30, 2017, and June 30, 2017, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could

12

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.

Claims and Litigation

PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

9.

Derivatives

We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in accumulated other comprehensive income (loss).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “—Fair Value Measurements.”

The following tables detail the Company’s outstanding derivatives that are designated and effective as cash flow hedges as of September 30, 2017:

Instrument	Hedge	Notional Amount at September 30, 2017	Fair value as of
			Consolidated Balance Sheet	September 30, 2017			June 30, 2017
Options	Brazilian Real calls​	R$19,500	Other current assets	​	$	1,781	​	$	2,686
Swap	Interest rate swap​	$ 150,000	Other assets	​	$	283	​	$	—

Instrument	Hedge	Gain (loss) recorded in OCI						Gain (loss) recognized in consolidated statements of operations							Consolidated Statement of Operations Line Item Total
		September 30, 2017			September 30, 2016			Consolidated Statement of Operations	September 30, 2017			September 30, 2016			September 30, 2017			September 30, 2016
Options	Brazilian Real calls	​	$	(905)	​	$	34	Cost of goods sold	​	$	186	​	$	(1,135)	​	$	130,030	​	$	126,988
Swap	Interest rate swap​	​	$	283	​	$	—	Interest expense, net	​	$	—	​	$	—	​	$	3,118	​	$	3,907

The foreign currency derivatives generally have an expiration or maturity of two years or less and are intended to hedge cash flows related to the purchase of inventory. These forecasted transactions are probable of occurring. As the hedged item is sold, we recognize the gain or loss recorded in accumulated other comprehensive income (loss) to the consolidated statements of operations on the same line where the hedged item is charged when released/sold. The fair values of the foreign currency options as of September 30, 2017, are unrealized and will fluctuate based on future exchange rates until the derivative contracts mature. Accumulated other comprehensive income (loss) at September 30, 2017 included $1,781 of net unrecognized gains on derivative instruments; we estimate the entire amount will be recognized in earnings within the next twelve months. At September 30, 2017, realized gains of $1,622 related to matured

13

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

contracts were recorded as a component of inventory. We anticipate these gains will be recognized as an offset to cost of goods sold within the next twelve months. At June 30, 2017, net realized gains of  $966 related to matured contracts were recorded as a component of inventory. We recognized $186 of these gains in cost of goods sold during the three months September 30, 2017, and anticipate we will recognize the remaining $780 of these gains in costs of goods sold in the next six months. We recognize gains (losses) related to these derivative instruments as a component of cost of goods sold at the time the hedged item is sold.

In July 2017, we entered into an interest rate swap agreement on $150,000 of notional principal that effectively converts the floating LIBOR or base rate portion of our interest obligation on that amount of debt, to a fixed interest rate of 1.8325% plus the applicable rate. The agreement matures concurrent with the Credit Agreement. The forecasted transactions are probable of occurring, and the interest rate swap has been designated as a highly effective cash flow hedge. The fair value of the interest rate swap agreement is recorded as an asset or liability with a corresponding amount included in accumulated other comprehensive income (loss).

10.

Fair Value Measurements

Contingent Consideration on Acquisitions

We determine the fair value of contingent consideration on acquisitions based on contractual terms, our current forecast of performance factors related to the acquired business and an applicable discount rate.

Derivatives

We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates, and interest rate curves.

Fair Value of Assets (Liabilities)

As of	September 30, 2017									June 30, 2017
​	Level 1			Level 2			Level 3			Level 1			Level 2			Level 3
Derivatives asset	​	$	—	​	$	1,781	​	$	—	​	$	—	​	$	2,686	​	$	—
Interest rate swap	​	$	—	​	$	283	​	$	—	​	$	—	​	$	—	​	$	—
Contingent consideration on acquisitions	​	$	—	​	$	—	​	$	(7,827)	​	$	—	​	$	—	​	$	(7,644)

The table below provides a summary of the changes in the fair value of Level 3 assets (liabilities):

Balance, June 30, 2017	$	(7,644)
Acquisition-related accrued interest	​	(253)
Payment	​	70
Balance, September 30, 2017	$	(7,827)

11.

Business Segments

The Animal Health segment manufactures and markets a broad range of products for food animals, including poultry, swine, cattle, dairy and aquaculture. The business includes net sales of medicated feed additives and other related products, nutritional specialty products and vaccines. The Mineral Nutrition segment manufactures and markets a broad range of trace minerals for food animals. The Performance Products segment manufactures and markets a variety of products for use in the personal care, automotive, industrial chemical and chemical catalyst industries.

14

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development. Corporate assets include cash and cash equivalents, certain debt issue costs, income tax related assets and certain other assets.

We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (e) certain items that we consider to be unusual, non-operational or non-recurring.

The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.

​	Three Months
For the Periods Ended September 30	2017			2016
Net sales	​			​
MFAs and other	​	$	79,603	​	$	83,419
Nutritional Specialties	​	​	30,777	​	​	26,304
Vaccines	​	​	18,461	​	​	14,778
Animal Health	​	​	128,841	​	​	124,501
Mineral Nutrition	​	​	52,073	​	​	51,592
Performance Products	​	​	12,498	​	​	11,894
Total segments	​	$	193,412	​	$	187,987
Depreciation and amortization	​			​
Animal Health	​	$	5,254	​	$	4,898
Mineral Nutrition	​	​	585	​	​	542
Performance Products	​	​	246	​	​	218
Total segments	​	$	6,085	​	$	5,658
Adjusted EBITDA	​			​
Animal Health	​	$	33,742	​	$	32,619
Mineral Nutrition	​	​	3,716	​	​	3,988
Performance Products	​	​	248	​	​	742
Total segments	​	$	37,706	​	$	37,349
Reconciliation of income before income taxes to Adjusted EBITDA	​			​
Income before income taxes	​	$	18,944	​	$	17,572
Interest expense, net	​	​	3,118	​	​	3,907
Depreciation and amortization – Total segments	​	​	6,085	​	​	5,658
Depreciation and amortization – Corporate	​	​	559	​	​	660
Corporate costs	​	​	7,589	​	​	7,524
Acquisition-related cost of goods sold	​	​	249	​	​	—
Acquisition-related accrued compensation	​	​	437	​	​	420
Acquisition-related transaction costs	​	​	400	​	​	1,274
Foreign currency (gains) losses, net	​	​	325	​	​	334
Adjusted EBITDA – Total segments	​	$	37,706	​	$	37,349

15

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
 

As of	September 30, 2017			June 30, 2017
Identifiable assets	​			​
Animal Health	​	$	479,075	​	$	442,521
Mineral Nutrition	​	​	60,371	​	​	55,184
Performance Products	​	​	22,331	​	​	23,681
Total segments	​	​	561,777	​	​	521,386
Corporate	​	​	109,334	​	​	102,011
Total	​	$	671,111	​	$	623,397

The Animal Health segment includes all goodwill of the Company. The Animal Health segment includes advances to and investment in an equity method investee of  $3,802 and $3,719 as of September 30, 2017 and June 30, 2017, respectively. The Performance Products segment includes an investment in equity method investee of  $559 and $516 as of September 30, 2017 and June 30, 2017, respectively. Corporate assets include cash and cash equivalents, certain debt issuance costs, income tax related assets and certain other assets.

16

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” and “Forward-Looking Statements.”

Overview of our business

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and performance and contribute to balanced mineral nutrition. We also manufacture and market specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries.

Trends and uncertainties

Our business depends heavily on a healthy and growing livestock industry. Some in the public perceive risks to human health related to the consumption of food derived from animals that utilize certain of our products, including certain of our MFA products. In particular, there is increased focus, primarily in the United States, on the use of medically important antimicrobials, as defined by the FDA. Medically important antimicrobials (“MIAs”) include classes that are prescribed in animal and human health and are listed in the Appendix of the FDA-CVM Guidance for Industry (GFI) 152. Our products that contain virginiamycin, oxytetracycline or neomycin have previously been classified by the FDA as medically important antimicrobials. This may lead to a decline in the demand for and production of food products derived from animals that utilize our MIA products and, in turn, demand for our MIA products. Livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of nutrition and health-related concerns, animal rights, and other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including us. In addition, campaigns by interest groups, activists and others with respect to perceived risks associated with the use of our products in animals, including position statements by livestock producers and their customers based on non-use of certain medicated products in livestock production, whether or not scientifically-supported, could affect public perceptions and reduce the use of our products. Those adverse consumer views related to the use of one or more of our products in animals could have a material adverse effect on our financial condition and results of operations.

Our sales in the United States of products classified by the FDA as medically important antimicrobials were approximately $18 million and $23 million for the twelve months ended September 30, 2017 and June 30, 2017, respectively.

Our business is subject to product registration and authorization regulations. Changes in the regulations could have a material impact on our business. In April 2016, the FDA began initial steps to withdraw approval of Mecadox (carbadox), due to concerns that certain residues from the product may persist in tissues for longer than previously determined. This initial action by the FDA does not prohibit the sale or use of Mecadox in the United States. In July 2016, we submitted our data, analyses and information to the FDA that we believe support the continued safe use of Mecadox. The timing of the FDA’s response to our submission is not subject to a predetermined deadline. Should we be unable to successfully defend the safety of the product, the loss of Mecadox sales would have a negative effect on the results of our operations.

Our sales in the United States of Mecadox were approximately $14 million for each of the twelve months ended September 30, 2017 and June 30, 2017, respectively.

17

Analysis of the consolidated statements of operations

Summary Results of Operations

​	Three Months
For the Periods Ended September 30	2017			2016			Change
​	(in thousands, except per share amounts and percentages)
Net sales	​	$	193,412	​	$	187,987	​	$	5,425	3%
Gross profit	​	​	63,382	​	​	60,999	​	​	2,383	4%
Selling, general and administrative expenses	​	​	40,995	​	​	39,186	​	​	1,809	5%
Operating income	​	​	22,387	​	​	21,813	​	​	574	3%
Interest expense, net	��	​	3,118	​	​	3,907	​	​	(789)	(20)%
Foreign currency (gains) losses, net	​	​	325	​	​	334	​	​	(9)	(3)%
Income before income taxes	​	​	18,944	​	​	17,572	​	​	1,372	8%
Provision (benefit) for income taxes	​	​	3,052	​	​	5,395	​	​	(2,343)	(43)%
Net income	​	$	15,892	​	$	12,177	​	$	3,715	31%
Net income per share	​			​			​			​
basic	​	$	0.40	​	$	0.31	​	$	0.09	​
diluted	​	$	0.39	​	$	0.31	​	$	0.08	​
Weighted average number of shares outstanding	​			​			​			​
basic	​	​	39,944	​	​	39,408	​	​	​	​
diluted	​	​	40,293	​	​	39,906	​	​	​	​
Ratio to net sales	​			​			​			​
Gross profit	​	​	32.8%	​	​	32.4%	​	​	​	​
Selling, general and administrative expenses	​	​	21.2%	​	​	20.8%	​	​	​	​
Operating income	​	​	11.6%	​	​	11.6%	​	​	​	​
Income before income taxes	​	​	9.8%	​	​	9.3%	​	​	​	​
Net income	​	​	8.2%	​	​	6.5%	​	​	​	​
Effective tax rate	​	​	16.1%	​	​	30.7%	​	​	​	​

Certain amounts and percentages may reflect rounding adjustments.

Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA

We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures” for descriptions of EBITDA and Adjusted EBITDA.

18

Segment net sales and Adjusted EBITDA:

​	Three Months
For the Periods Ended September 30	2017			2016			Change
​	(in thousands, except percentages)
Net sales	​			​			​			​
MFAs and other	​	$	79,603	​	$	83,419	​	$	(3,816)	(5)%
Nutritional specialties	​	​	30,777	​	​	26,304	​	​	4,473	17%
Vaccines	​	​	18,461	​	​	14,778	​	​	3,683	25%
Animal Health	​	​	128,841	​	​	124,501	​	​	4,340	3%
Mineral Nutrition	​	​	52,073	​	​	51,592	​	​	481	1%
Performance Products	​	​	12,498	​	​	11,894	​	​	604	5%
Total	​	$	193,412	​	$	187,987	​	$	5,425	3%
Adjusted EBITDA	​			​			​			​
Animal Health	​	$	33,742	​	$	32,619	​	$	1,123	3%
Mineral Nutrition	​	​	3,716	​	​	3,988	​	​	(272)	(7)%
Performance Products	​	​	248	​	​	742	​	​	(494)	(67)%
Corporate	​	​	(7,589)	​	​	(7,524)	​	​	(65)	*
Total	​	$	30,117	​	$	29,825	​	$	292	1%
Adjusted EBITDA ratio to segment net sales	​			​			​			​
Animal Health	​	​	26.2%	​	​	26.2%	​			​
Mineral Nutrition	​	​	7.1%	​	​	7.7%	​			​
Performance Products	​	​	2.0%	​	​	6.2%	​			​
Corporate(1)	​	​	(3.9)%	​	​	(4.0)%	​			​
Total(1)	​	​	15.6%	​	​	15.9%	​			​

(1)

reflects ratio to total net sales

The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

​	Three Months
For the Periods Ended September 30	2017			2016			Change
​	(in thousands, except percentages)
Net income	​	$	15,892	​	$	12,177	​	$	3,715	31%
Interest expense, net	​	​	3,118	​	​	3,907	​	​	(789)	(20)%
Provision (benefit) for income taxes	​	​	3,052	​	​	5,395	​	​	(2,343)	(43)%
Depreciation and amortization	​	​	6,644	​	​	6,318	​	​	326	5%
EBITDA	​	​	28,706	​	​	27,797	​	​	909	3%
Acquisition-related cost of goods sold	​	​	249	​	​	—	​	​	249	*
Acquisition-related accrued compensation	​	​	437	​	​	420	​	​	17	4%
Acquisition-related transaction costs	​	​	400	​	​	1,274	​	​	(874)	(69)%
Foreign currency (gains) losses, net	​	​	325	​	​	334	​	​	(9)	(3)%
Adjusted EBITDA	​	$	30,117	​	$	29,825	​	$	292	1%

Certain amounts and percentages may reflect rounding adjustments.

*

Calculation not meaningful

19

Comparison of three months ended September 30, 2017 and 2016

Net sales

Net sales of $193.4 million for the three months ended September 30, 2017, increased $5.4 million, or 3%, as compared to the three months ended September 30, 2016. Animal Health, Performance Products and Mineral Nutrition grew $4.3 million, $0.6 million and $0.5 million respectively.

Animal Health

Net sales of $128.8 million for the three months ended September 30, 2017, grew $4.3 million, or 3%. The growth was primarily due to volume increases in the nutritional specialty and vaccine product groups within the segment. Nutritional specialty products grew $4.5 million, or 17%, primarily due to volume growth of our products for the U.S. poultry and dairy industries. Vaccines grew $3.7 million, or 25%, primarily due to volume growth of our products for the poultry and swine industries. MFAs and other declined $3.8 million, or 5%, primarily due to volume declines. Domestic net sales of MFAs and other declined $10.5 million due to $4.2 million lower sales of medically important antimicrobials and due to unfavorable timing of certain customer orders. International net sales increased $6.7 million due to growth across most regions, including the benefit of improved economic conditions in Brazil.

Mineral Nutrition

Net sales of $52.1 million increased $0.5 million, or 1%, for the three months ended September 30, 2017. The increased revenue was primarily due to higher average selling prices resulting from underlying raw material commodity price increases. The increase in average selling prices was partially offset by lower volumes of trace mineral products due to customer demand.

Performance Products

Net sales of $12.5 million increased $0.6 million, or 5%, for the three months ended September 30, 2017, due to higher average selling prices and higher volumes of copper-based products.

Gross profit

Gross profit of $63.4 million for the three month ended September 30, 2017, increased $2.4 million, or 4%, as compared to the three months ended September 30, 2016. Gross profit increased to 32.8% of net sales for the three months ended September 30, 2017, as compared to 32.4% for the three months ended September 30, 2016. The three months ended September 30, 2017, included $0.2 million of acquisition-related cost of goods sold. Depreciation expense included in cost of goods sold increased $0.5 million due to recent capital expenditures. Excluding the effects of the acquisition-related cost of goods sold and increased depreciation, Animal Health gross profit increased $3.7 million due to volume growth in nutritional specialty and vaccine products, as well as lower unit costs from improved operating efficiencies, partially offset by volume declines in MFAs and other products. Mineral Nutrition gross profit decreased $0.2 million due to higher raw material costs, partially offset by higher average selling prices. Performance Products gross profit decreased $0.4 million due to higher product costs for copper-based products, partially offset by higher average selling prices of copper-based products.

Selling, general and administrative expenses

SG&A of $41.0 million for the three months ended September 30, 2017, increased $1.8 million, or 5%, as compared to the three months ended September 30, 2016. SG&A for the three months ended September 30, 2017 and 2016, included $0.4 million and $1.3 million, in acquisition-related transaction costs, respectively. Excluding these costs, SG&A increased $2.7 million, or 7%, for the year.

Animal Health SG&A increased $2.5 million, driven by sales force expansion and product development costs. Mineral Nutrition and Performance increased $0.1 million and $0.2 million, respectively. Excluding the acquisition-related transaction costs, Corporate decreased less than $0.1 million, as reduced pension costs offset increases in other expenses.

20

Interest expense, net

Interest expense, net of $3.1 million for the three months ended September 30, 2017, decreased $0.8 million, or 20%, as compared to the three months ended September 30, 2016. Interest expense decreased $1.2 million compared to the prior year, primarily due to lower interest rates in the new Credit Facilities completed in June 2017. Interest income decreased $0.4 million due to less interest on deposits in foreign jurisdictions.

Foreign currency (gains) losses, net

Foreign currency (gains) losses, net for the three months ended September 30, 2017, amounted to net losses of $0.3 million, as compared to $0.3 million in net losses for the three months ended September 30, 2016. Foreign currency losses in the three months ended September 30, 2017, were primarily due to the movement of the South African and Mexican currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.

Provision (benefit) for income taxes

The provision for income taxes was $3.1 million and $5.4 million for the three months ended September 30, 2017 and 2016, respectively. The effective income tax rates for these periods were 16.1% and 30.7%, respectively. The provisions for income taxes for the three months ended September 30, 2017 included a benefit of  $2.7 million from the exercise of employee stock options. Without the benefit, the effective income tax rates for the three months ended September 30, 2017 would have been 30.6%.

Net income

Net income of $15.9 million for the three months ended September 30, 2017, increased $3.7 million, as compared to net income of $12.2 million for the three months ended September 30, 2016. The increase was a result of the factors described above, including a $2.3 million reduction in income tax expense and a $0.8 million reduction in interest expense, net.

Adjusted EBITDA

Adjusted EBITDA of $30.1 million for the three months ended September 30, 2017, increased $0.3 million, or 1%, as compared to the three months ended September 30, 2016. Animal Health Adjusted EBITDA increased $1.1 million, or 3%, due to sales growth and increased gross profit, partially offset by increased SG&A. Mineral Nutrition Adjusted EBITDA decreased $0.3 million, or 7%, due to higher raw material costs, partially offset by higher average selling prices. Performance Products Adjusted EBITDA decreased $0.5 million, due to higher product costs, partially offset by higher average selling prices. Corporate expenses increased $0.1 million due to increased compensation and benefit costs, partially offset by lower pension costs.

Pension Plan and Retirement Savings Plan Changes

In July 2016, we amended our domestic noncontributory defined benefit pension plan to eliminate credit for future service and compensation increases, effective as of September 30, 2016. The amendment resulted in a curtailment of the pension plan. During the three months ended September 30, 2016, we recorded a pension curtailment gain of $6.8 million in other comprehensive income and an offsetting reduction in the liability for pension benefits included in other liabilities. We also modified the 401(k) retirement savings plan effective October 1, 2016, to include, for all domestic employees, a non-elective Company contribution of 3% of compensation and an additional discretionary contribution of up to 4% of compensation, depending on the employee’s age and years of service.

21

Analysis of financial condition, liquidity and capital resources

Net increase (decrease) in cash and cash equivalents was:

​	Three Months
For the Periods Ended September 30	2017			2016			Change
​	(in thousands)
Cash provided by/(used in):	​			​			​
Operating activities	​	$	4,803	​	$	21,456	​	$	(16,653)
Investing activities	​	​	(16,832)	​	​	(5,886)	​	​	(10,946)
Financing activities	​	​	17,845	​	​	(11,670)	​	​	29,515
Effect of exchange-rate changes on cash and cash equivalents	​	​	198	​	​	(90)	​	​	288
Net increase/(decrease) in cash and cash equivalents	​	$	6,014	​	$	3,810	​	$	2,204

Net cash provided (used) by operating activities was comprised of:

​	Three Months
For the Periods Ended September 30	2017			2016			Change
​	(in thousands)
EBITDA	​	$	28,706	​	$	27,797	​	$	909
Acquisition-related cost of goods sold	​	​	249	​	​	—	​	​	249
Acquisition-related accrued compensation	​	​	437	​	​	420	​	​	17
Acquisition-related transaction costs	​	​	400	​	​	1,274	​	​	(874)
Foreign currency (gains) losses, net	​	​	325	​	​	334	​	​	(9)
Interest paid	​	​	(2,679)	​	​	(3,770)	​	​	1,091
Income taxes paid	​	​	(4,039)	​	​	(3,717)	​	​	(322)
Changes in operating assets and liabilities and other items	​	​	(18,196)	​	​	392	​	​	(18,588)
Cash used for acquisition-related transaction costs	​	​	(400)	​	​	(1,274)	​	​	874
Net cash provided (used) by operating activities	​	$	4,803	​	$	21,456	​	$	(16,653)

Certain amounts may reflect rounding adjustments.

Operating activities

Net cash provided by operating activities was $4.8 million for the three months ended September 30, 2017. Cash provided by net income and non-cash charges, including depreciation and amortization, was partially offset by $18.2 million of cash used in the ordinary course of business for changes in operating assets and liabilities and other items. Accounts receivable used $8.4 million of cash due to the timing of sales and collections in international regions. Increased inventories used $5.2 million of cash due to the timing of sales, purchases and production; a $3.7 million source of cash from increased accounts payable was primarily related to the timing of inventory purchases. Seasonality was a significant reason for the increases in inventories and accounts payable. Accrued expenses and other liabilities, excluding the effect of changes in accrued income tax and interest, used $4.4 million of cash primarily due to annual incentive compensation payments.

Investing activities

Net cash used in investing activities was $16.8 million for the three months ended September 30, 2017. Cash used for an acquisition of a business was $11.6 million. Capital expenditures were $5.0 million as we continued to invest in our existing asset base and for capacity expansion and productivity improvements. Other investing activities used $0.3 million of cash.

22

Financing activities

Net cash provided by financing activities was $17.9 million for the three months ended September 30, 2017. Net borrowings on our Revolver provided $20.0 million. We received $3.5 million from the issuance of common shares related to the exercise of stock options. We paid $4.0 million in dividends to holders of our Class A and Class B common stock. We paid $1.7 million in scheduled debt and other requirements.

Liquidity and capital resources

We believe our cash on hand, our operating cash flows and our financing arrangements, including the availability of borrowings under the Revolver and foreign credit lines, will be sufficient to support our future cash needs. Our operating plan projects adequate liquidity throughout the year. However, we can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the Credit Facilities and foreign credit lines based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that the challenging economic environment or an economic downturn would not impact our liquidity or our ability to obtain future financing. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources follow:

As of	September 30, 2017			June 30, 2017			Change
​	(in thousands, except ratios)
Cash and cash equivalents	​	$	62,097	​	$	56,083	​	$	6,014
Working capital	​	​	219,246	​	​	198,036	​	​	21,210
Ratio of current assets to current liabilities	​	​	2.94:1	​	​	2.81:1	​	​	​

We define working capital as total current assets (excluding cash and cash equivalents) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

At September 30, 2017, we had $85.0 million in outstanding borrowings under the Revolver. We had outstanding letters of credit and other commitments of  $4.7 million, leaving $160.3 million available for borrowings and letters of credit.

We currently intend to pay quarterly dividends of  $0.10 per share, representing $16.1 million annually on our Class A and Class B common stock, subject to approval from the Board of Directors. We declared and paid a cash dividend of  $0.10 per share on Class A and Class B common stock during the three months ended September 30, 2017. On November 6, 2017, our Board of Directors declared a cash dividend of  $0.10 per share on each share of our Class A and Class B common stock outstanding on the record date of December 6, 2017, payable on December 27, 2017.

At September 30, 2017, our cash and cash equivalents included $59.0 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.

Contractual obligations

As of September 30, 2017, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report on Form 10-K for the year ended June 30, 2017.

Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

23

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

General description of non-GAAP financial measures

Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to portray the results of our operations prior to considering certain income statement elements. We have defined EBITDA as net income (loss) plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We have defined Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income.

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

•

senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;

•

our annual budgets are prepared on an Adjusted EBITDA basis; and

•

other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies.

Certain significant items

Adjusted EBITDA is calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. An example of an unusual item is the loss on extinguishment of debt incurred in fiscal year 2017. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

New accounting standards

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”

24

Critical Accounting Policies

Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, legal and environmental matters and actuarial assumptions related to our pension plans. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in the Annual Report. As of September 30, 2017, there have been no material changes to any of the critical accounting policies contained therein.

Forward-Looking Statements

This report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

•

perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;

•

restrictions on the use of antibacterials in food-producing animals may become more prevalent;

•

a material portion of our sales and gross profits are generated by antibacterials and other related products;

•

competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;

•

the impact of current and future laws and regulatory changes;

•

outbreaks of animal diseases could significantly reduce demand for our products;

•

our ability to successfully implement several of our strategic initiatives;

•

our business may be negatively affected by weather conditions and the availability of natural resources;

•

the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;

25

•

our ability to control costs and expenses;

•

any unforeseen material loss or casualty;

•

exposure relating to rising costs and reduced customer income;

•

competition deriving from advances in veterinary medical practices and animal health technologies;

•

unanticipated safety or efficacy concerns;

•

our dependence on suppliers having current regulatory approvals;

•

our raw materials are subject to price fluctuations and their availability can be limited;

•

natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;

•

terrorist attacks, particularly attacks on or within markets in which we operate;

•

our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;

•

adverse U.S. and international economic market conditions, including currency fluctuations;

•

the risks of product liability claims, legal proceedings and general litigation expenses;

•

our dependence on our Israeli and Brazilian operations;

•

our substantial level of indebtedness and related debt-service obligations;

•

restrictions imposed by covenants in our debt agreements;

•

the risk of work stoppages; and

•

other factors as described in “Risk Factors” in Item 1A. of the Annual Report.

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Annual Report. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

Item 3.   Quantitative and Qualitative Disclosures about Market Risk

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We also utilize, on a limited basis, certain commodity derivatives, primarily on copper used in manufacturing processes, to hedge the cost of anticipated purchase or supply

26

requirements. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that completely eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

For financial market risks related to changes in interest rates, foreign currency exchange rates and commodity prices, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. There were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

Item 4.   Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)). Based upon that evaluation as of September 30, 2017, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were not effective because of material weaknesses in our internal control over financial reporting, as described in Management’s Report on Internal Control over Financial Reporting in “Item 9A. Controls and Procedures” in the Annual Report on Form 10-K for the year ended June 30, 2017.

Management’s Remediation Plan

We are in the process of implementing a broad range of changes to our internal control over financial reporting to remediate the material weaknesses that existed as of June 30, 2017. Our actions to address material weaknesses have included the design and implementation of additional formal accounting policies and procedures to ensure transactions are properly initiated, recorded, processed, reported, appropriately authorized and approved. Also, our efforts to ensure maintenance of the appropriate level of segregation of duties includes restricting access to key financial systems and records to appropriate users. We are determining the extent it is necessary to limit access by and modify responsibilities of certain personnel, as well as designing and implementing additional user access controls and compensating controls. We will continue to build on the progress we have made in our remediation plan. We cannot determine when our remediation plan will be fully completed, and we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

Changes in Internal Control over Financial Reporting

There have been no changes in internal control over financial reporting during the three months ended September 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

27

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

Information required by this Item is incorporated herein by reference to “Notes to the Consolidated Financial Statements—Commitments and Contingencies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.

Item 1A.

Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Risk Factors” section in the Annual Report, which could materially affect our business, financial condition or future results.

There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

None.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit 31.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302

Exhibit 31.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302

Exhibit 32.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906

Exhibit 32.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906

Exhibit 101.INS* XBRL Instance Document

Exhibit 101.SCH* XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document

Exhibit 101.LAB* XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

*

Furnished with this Quarterly Report. Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933 and are deemed not filed for purposes of section 18 of the Exchange Act.

28

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​	Phibro Animal Health Corporation
November 6, 2017	By:	/s/ Jack C. Bendheim Jack C. Bendheim Chairman, President and Chief Executive Officer
November 6, 2017	By:	/s/ Richard G. Johnson Richard G. Johnson Chief Financial Officer

29